Financing and liquidity risk
The company has incurred losses since inception and expects continued losses before commercialization scales.
- Scope
- Cash on hand, future equity/debt access, and commercialization timing
- Materiality
- high
Cibus, Inc.
Cibus, Inc. develops gene-edited plant traits using its proprietary RTDS platform, with a current focus on weed-management traits for rice and canola. The company also pursues partner-funded sustainable ingredients and other trait programs, monetizing its technology through collaboration agreements, licenses, and future royalties rather than selling finished farm products.
−2 517,3 %
−3 492,3 %
−14,6 %
0.72
0.72
| % | |
|---|---|
| Gene editing platform | 0% Core RTDS technology used to edit elite germplasm with targeted trait changes. |
| Rice traits | 45% Herbicide tolerance and stacked trait lines for rice commercialization. |
| Canola and WOSR traits | 15% Trait development for canola and winter oilseed rape, including disease resistance work. |
| Soybean traits | 10% Soybean editing programs such as HT2 used to expand the platform and future partnerships. |
| Sustainable ingredients and biofragrance | 30% Partner-supported ingredient and fermentation-based product development programs. |
Cibus sells primarily to seed companies, agricultural partners, and prospective commercial licensees that want...
- Seed companies and breeding partnersprimary
Buy trait access and edited germplasm to incorporate Cibus traits into commercial seed lines.
- Agricultural collaboration partnersprimary
Fund contract research and development milestones for rice, canola, and other traits.
- Consumer-packaged goods partnersecondary
Supports sustainable ingredients development and helps fund commercialization work.
- Prospective rice commercial customersprimary
Engage for rice herbicide tolerance traits in geographies where rice is cultivated globally.
- Future licensees and royalty partnersemerging
Would commercialize products containing Cibus intellectual property and pay fees or royalties.
Cibus is headquartered in the United States and conducts development work across the U.S...
- •United States is the home market and a key regulatory reference point
- •Ecuador provided regulatory validation for RTDS technologies
- •Latin America is a near-term rice commercialization focus
- •UK regulatory progress may lower barriers for precision-bred organisms
- •Global rice-growing geographies are the target market for future launches
Cibus is narrowing its focus to weed management in rice and partner-supported sustainable ingredients to preserve...
01
Commercialize rice herbicide tolerance traitsshort-term
Rice is the clearest near-term path to revenue and customer adoption.
02
Convert RTDS validation into broader regulatory acceptancemedium-term
Lower regulatory barriers should shorten development cycles and expand addressable markets.
03
Preserve capital and reduce burnshort-term
The company remains loss-making and needs runway to reach commercialization milestones.
04
Monetize partner-funded sustainable ingredientsmedium-term
This provides non-dilutive funding and diversifies the revenue base.
Cibus remains an early-commercial biotech company with limited revenue, ongoing losses, and dependence on external...
Commercialization delay in rice traits
Revenue depends on moving edited traits into customer germplasm and achieving regulatory clearance and adoption.
- Scope
- Latin America launch timing, U.S. expansion, customer conversion
- Materiality
- high
Regulatory risk
Gene-edited crop commercialization depends on evolving rules in each market.
- Scope
- United States, Ecuador, UK, EU
- Materiality
- high
Restructuring execution risk
Workforce and facility reductions may reduce institutional knowledge and disrupt development.
- Scope
- Talent retention, morale, operational continuity
- Materiality
- medium
Litigation and contingent liability risk
The company accrued a liability related to a Ninth Circuit decision and insurance proceeds repayment.
- Scope
- Cash outflow and earnings impact
- Materiality
- medium
Revenue recognition for collaboration agreements
Quarterly revenue volatility
Goodwill impairment
Non-cash operating loss volatility
Litigation liability accrual
Balance sheet liability and earnings impact
Going concern and liquidity estimates
Disclosure risk and investor perception of runway
Restructuring and lease exit accounting
Expense timing and cash usage
: 28.4.2026